The efficacy and safety of Ferriprox for the treatment of transfusional iron overload in patients with sickle cell disease or other anemias
- Determine the efficacy of deferiprone versus the standard chelator, deferoxamine, for the treatment of iron overload in individuals with sickle cell disease and other anemias.
- Evaluate the effect of deferiprone vs deferoxamine on patients' quality of life.
- Evaluate the safety and tolerability of deferiprone vs deferoxamine.
Patients age 2 and older with sickle cell disease or other condition with iron overload from repeated blood transfusions (excluding thalassemia and bone marrow failure syndromes) with baseline liver iron >7 mg/g dw, <30 mg/g dw
PI: Dr. Janet Kwiatkowski
SC: Helen Stanley, Jolene Kokroko
Sponsor: ApoPharma Pharmaceuticals